Mayo Clinic Laboratories has entered a strategic collaboration with Singapore-based molecular diagnostics company Lucence to expand advanced cancer testing services.
The collaboration will leverage the individual capabilities of both organisations to provide better outcomes for patients.
It aims to provide healthcare providers with the tools they need to make informed decisions and deliver personalised treatment plans for their patients.
Mayo Clinic Laboratories president and CEO William Morice said: “We look forward to making LiquidHALLMARK available so physicians and their patients have access to important insights that can inform treatment decisions.
“Incorporating this test into our catalogue supports our goal of offering comprehensive testing options for serious or complex cases.”
With CLIA-licensed and CAP-accredited laboratories in California and Singapore, Lucence will provide its advanced LiquidHALLMARK technology through Mayo Clinic Laboratories.
LiquidHALLMARK is an ultra-sensitive, sequencing liquid biopsy that analyses circulating tumour DNA (ctDNA) and RNA (ctRNA) for biomarkers across different cancers.
Recently, Lucence has received Medicare coverage for its LiquidHALLMARK ctDNA/ctRNA liquid biopsy test, under the Molecular Diagnostic Services (MolDX) Programme.
The Medicare-covered test provides actionable findings that enable targeted therapies, including detailed descriptions of each finding and associated clinical trials.
Its reports include graphical maps for understanding cancer genomic profiles and tracking tumour changes over time, along with detailed information on each genomic finding.
The test results will highlight the role of each finding in the patient’s cancer type and existing functional evidence.
Lucence founding CEO and medical director Min-Han said: “Working with Mayo Clinic Laboratories will advance our shared goal of making innovative cancer tests available to benefit everyone globally.
“Combining Lucence’s liquid biopsy testing with Mayo Clinic Laboratories’ broad reach and expertise means that healthcare providers everywhere can be empowered with important information to improve personalised cancer care.”
Mayo Clinic Laboratories is a fully owned subsidiary of US-based non-profit academic medical centre Mayo Clinic.
Mayo Clinic will use any revenue from the collaboration to support its not-for-profit mission in patient care, education, and research.
